Monica Bertagnolli, former director of NIH and NCI, is on the path to becoming the next president of the National Academy of Medicine.
Break Through Cancer has launched the Defying Osteosarcoma TeamLab, an initiative that brings together more than 20 researchers from eight institutions in a coordinated, multi-year effort focused on improving pediatric osteosarcoma care.
Twelve leading research teams from around the world have been shortlisted for Cancer Grand Challenges’ fifth funding round. The teams will present final proposals to a panel of leading international scientists in December, with winners receiving up to £20 million each.Â
Nicholas Richardson was named vice president of clinical development at Precision for Medicine, a company focused on biomarker-driven clinical research and development.
Scott Eggener was named chair of the Department of Urology at the David Geffen School of Medicine at UCLA and executive medical director for urology for the UCLA Health system.
UC Davis Health and UCLA are co-leading a newly funded national clinical trial to evaluate whether AI can help radiologists interpret screening mammograms more accurately. The goal is to improve breast cancer detection and reduce unnecessary callbacks and anxiety for patients.
Kimberly Leslie, a professor at the University of New Mexico Comprehensive Cancer Center, was awarded a 5-year, $12.9 million grant from NCI. Leslie and her research team, which includes scientists from the Universities of Iowa, Utah, Kansas, Virginia, and California at San Diego, will study all available hormonal regimens to prevent and treat endometrial cancer.
The Wistar Institute is opening the Center for Advanced Therapeutics to speed up the creation of new drugs and therapies for human health. The CAT is led by Paul Lieberman and capitalizes on a history of Wistar research in cancer, immunology, and infectious disease.
Haystack Oncology, a Quest Diagnostics company, and Rutgers Cancer Institute are partnering to evaluate the use of Haystack MRD, a circulating tumor DNA minimal residual disease test, to help optimize postoperative therapy decisions in patients with stage 2/3 non-small cell lung cancer.Â
Moffitt Cancer Center and Tampa-based Mainsail Lodging & Development announced a partnership to bring a new 200-room, full-service hotel to Moffitt’s McKinley Campus. Expected to open in summer 2028, the hotel aims to enhance the experience of patients, families, visiting physicians and scientists, and the broader community.
